日本国立癌症研究中心东医院
- 发布时间:2020-01-22 12:45
秋元 哲夫Tetsuo Akimoto, MD, PhD
职位名称
- 重离子医学开发分会长
- 东医院 副院長(教育担当)、放射线治疗科长 秋元 哲夫
- 东京女子医科大学 客座教授
专业领域
- 放射线治疗
- 粒子线治疗
关键词
- 放射线治疗
- 质子线治疗
- 临床试验
- 化学放射线疗法
- 放射线生物
现在主要研究主题
- 质子线治疗相关的技术开发
- 利用质子线治疗的临床试验
- 高精度放射线治疗
共同研究的可行性主题
- 放射线治疗・重离子治疗的临床试验
- 化学放射性疗法
- 强度变化放射线治疗
主な所属学会
- American Society for Therapeutic Radiology and Oncology
- American Society of Clinical Oncology
- American Association for Cancer Research
- 日本癌学会
- 日本癌治疗学会
- 日本医学放射线学会
- 日本放射线肿瘤学会
- 日本头颈部癌学会
- 日本食道学会
- 日本乳癌学会
- 日本癌分子标的治疗学会 等
主要论文
- Hotta K, Kohno R, Nagafuchi K, Yamaguchi H, Tansho R, Takada Y, Akimoto T. Evaluation of monitor unit calculation based on measurement and calculation with a simplified Monte Carlo method for passive beam delivery system in proton beam therapy. J Appl Clin Med Phys, 16:5419, 2015
- Zenda S, Ishi S, Akimoto T, Arahira S, Motegi A, Tahara M, Hayashi R, Asanuma C. DeCoP, a Dermatitis Control Program using a moderately absorbent surgical pad for head and neck cancer patients receiving radiotherapy: a retrospective analysis. Jpn J Clin Oncol, 45: 433-438, 2015
- Tahara M, Kiyota N, Mizusawa J, Nakamura K, Hayashi R, Akimoto T, Hasegawa Y, Iwae S, Monden N, Matsuura K, Fujii H, Onozawa Y, Homma A, Kubota A, Fukuda H, Fujii M. Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706). Cancer Sci, 106:726-733, 2015
- Mizowaki T, Aoki M, Nakamura K, Yorozu A, Kokubo M, Karasawa K, Kozuka T, Nakajima N, Sasai K, Akimoto T. Current status and outcomes of patients developing PSA recurrence after prostatectomy who were treated with salvage radiotherapy: a JROSG surveillance study. J Radiat Res, 56:750-756, 2015
- Hashimoto Y, Akimoto T, Iizuka J, Tanabe K, Mitsuhashi N. Correlation between the changes in the EPIC QOL scores and the dose-volume histogram parameters in high-dose-rate brachytherapy combined with hypofractionated external beam radiation therapy for prostate cancer. Jpn J Clin Oncol, 45:81-87, 2015
- Zenda S, Kawashima M, Arahira S, Kohno R, Nishio T, Tahara M, Hayashi R, Akimoto T. Late toxicity of proton beam therapy for patients with the nasal cavity, para-nasal sinuses, or involving the skull base malignancy: importance of long-term follow-up. Int J Clin Oncol, 20:447-454, 2015
- Maebayashi T, Ishikawa H, Yorozu A, Yoshida D, Katoh H, Nemoto K, Ishihara S, Takemoto S, Ishibashi N, Tokumaru S, Akimoto T on behalf of Working Subgroup of Urological Cancers in Japanese Radiation Oncology Study Group. Patterns of practice in the radiation therapy for bladder cancer: survey of the Japanese Radiation Oncology Study Group (JROSG). Jpn J Clin Oncol, 44:1109-1115, 2014
- Shinozaki T, Hayashi R Miyazaki M, Tomioka T, Zenda S, Tahara T, Akimoto T. Gastrostomy dependence in head and neck carcinoma patient receiving post-operative therapy. Jpn J Clin Oncol, 44:1058-1062, 2014
- Motegi A, Kawashima M, Arahira S, Zenda S, Toshima M, Onozawa M, Hayashi R, Akimoto T. Accelerated radiotherapy for T1 to T2 glottic cancer. Head Neck, 37:579-584, 2015
- Motegi K, Kohno R, Ueda T, Shibuya T, Ariji T, Kawashima M, Akimoto T. Evaluating positional accuracy using megavoltage cone-beam computed tomography for IMRT with head-and-neck cancer. J Radiat Res, 55:568-574, 2014
- Aoki M, Mizowaki T, Akimoto T, Nakamura K, Ejima Y, Jingu K, Tamai Y, Nakajima N, Takemoto S, Kokubo M, Katoh H. Adjuvant radiotherapy after prostatectomy for prostate cancer in Japan: a multi-institutional survey study of the JROSG. J Radiat Res, 55: 533-540, 2014
- Tansho R, Takada Y, Kohno R, Hotta K, Hara Y, Mizutani S, Akimoto T. Experimental verification of dose calculation using the simplified Monte Carlo method with an improved initial beam model for a beam-wobbling system. Phys Med Biol, 58:6047-6064, 2013
- Kawashima M, Ariji T, Kameoka S, Ueda T, Kohno R, Nishio T, Arahira S, Motegi A, Zenda S, Akimoto T, Tahara M, Hayashi R. Locoregional control after intensity-modulated radiotherapy for nasopharyngeal carcinoma with an anatomy-based target definition. Jpn J Clin Oncol, 43:1218-1225, 2013
- Zenda S, Nakagami Y, Toshima M, Arahira S, Kawashima M, Matsumoto Y, Kinoshita H, Satake M, Akimoto T. Strontium-89 (Sr-89) chloride in the treatment of various cancer patients with multiple bone metastases. Int J Clin Oncol, 19:739-743, 2014
- Matsubara K, Kohno R, Nishioka S, Shibuya T, Ariji T, Akimoto T, Saitoh H. Experimental evaluation of actual delivered dose using mega-voltage cone-beam CT and direct point dose measurement. Med Dosim, 38:153-159, 2013
- Kiyozuka M, Akimoto T, Fukutome M, Motegi A, Mitsuhashi N. Radiation-induced dimer formation of EGFR: implications for the radiosensitizing effect of cetuximab. Anticancer Res, 33:4337-4346, 2013
- Okano S, Yoshino T, Fujii M, Onozawa Y, Kodaira T, Fujii H, Akimoto T, Ishikura S, Oguchi M, Zenda S, de Blas B, Tahara M. Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck. Jpn J Clin Oncol, 43:476-482, 2013
- Sugimoto M, Gotohda N, Kato Y, Takahashi S, Kinoshita T, Shibasaki H, Kojima M, Ochiai A, Zenda S, Akimoto T, Konishi M. Pancreatic resection for metastatic melanoma originating from the nasal cavity: a case report and literature review. Anticancer Res, 33:567-573, 2013
- Nakamura K, Akimoto T, Mizowaki T, Hatano K, Kodaira T, Nakamura N, Kozuka T, Shikama N, Kagami Y. Patterns of practice in intensity-modulated radiation therapy and image-guided radiation therapy for prostate cancer in Japan. Jpn J Clin Oncol, 42:53-57, 2012
- Hojo H, Zenda S, Akimoto T, Kohno R, Kawashima M, Arahira S, Nishio T, Tahara M, Hayashi R, Sasai K. Impact of early radiological response evaluation on radiotherapeutic outcomes in the patients with nasal cavity and paranasal sinus malignancies. J Radiat Res, 53:704-709, 2012
- Okamoto M, Ishikawa H, Ebara T, Kato H, Tamaki T, Akimoto T, Ito K, Miyakubo M, Yamamoto T, Suzuki K, Takahashi T, Nakano T. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate. Int J Radiat Oncol Biol Phys, 82:211-217, 2012
- Zenda S, Matsuura K, Tachibana H, Homma A, Kirita T, Monden N, Iwae S, Ota Y, Akimoto T, Otsuru H, Tahara M, Kato K, Asai M. Multicenter phase II study of an opioid-based pain control program for head and neck cancer patients receiving chemoradiotherapy. Radiother Oncol, 101:410-414, 2011
在癌症治疗中,放疗导致的第二原发癌问题越来越受到人们的关注。高剂量放射线照射对肿瘤周围正常组织有害,但降低剂量,可能会影响到对肿瘤的控制效果。质子治疗是一种可以产生高能量,定位精准而且对周围组织伤害小的放疗手段,在现代癌症治疗过程中发挥了很大作用。日本国立癌症研究中心东医院是亚洲最早引进质子治疗系统,也是世界上第二家开始临床应用的综合医院。
质子治疗是利用失掉电子的氢原子原子核,经回旋加速器或者同步加速器加速到光速约70%,高速穿透到人体内部,到达肿瘤病灶区域,然后速度突然降低并停止,释放出最大能量,产生具有强大杀伤力的布拉格峰,将癌细胞杀死,同时有效地保护周围正常组织不受损害。
日本国立癌症研究中心东医院的质子治疗系统是由称为回旋加速器的质子束加速器和两个旋转式门架辐照室组成。它也是日本国内第一台安装在医院的质子束治疗系统,自1998年以来一直接受并治疗患者。
医院将质子的最大能量设置为235 MeV,使质子束可在人体内达到25厘米的深度。速度大约是60%的光速,相当于一秒钟绕地球4周半的速度。医院使用重达220吨的回旋加速器装置来生成高能量的质子束,再用电磁铁引导,通过治疗室背面的龙门发射架改变照射方向,把质子束照射到患者身上。龙门架是一个巨大的装置,配有电磁铁,通过旋转它可以360度地在病人周围的任何地方进行照射。
凡是需要放疗的患者都可选择质子治疗。质子治疗在某些解剖部位肿瘤有一定的优势。对于体内深部早期肿瘤,特别当手术可引起较高并发症、病死率和费用时,质子治疗可取代手术治疗且疗效不低于手术治疗;此外,质子治疗可能对年老体弱患者、合并使用化疗或手术患者有一定的优势。儿童肿瘤和二程放疗患者也可能是质子治疗受益比较大的群体。
质子治疗还可应用于联合化疗治疗。质子治疗可使骨髓、心脏、肾脏、肺等化疗易损伤的器官免受照射或降低其吸收剂量,因此可联合使用强效化疗方案。例如质子治疗髓母细胞瘤时可避开耳蜗,因此可降低联合顺铂化疗造成的听力受损;质子治疗联合使用阿霉素治疗左侧乳腺癌时,可降低严重心肌病变的发生。
此外,质子治疗可联合手术治疗大体积肿瘤或贴近危及器官肿瘤。大体积肿瘤往往是预示肿瘤晚期 ,肿瘤贴近危及器官增加了肿瘤治疗的难度。质子治疗前选择性的手术治疗,可减轻肿瘤负荷 ,加大肿瘤组织和危及器官间的间隙;术前质子治疗可减小肿瘤体积,创造彻底切除肿瘤和保全器官功能的机会。
日本国立癌症研究中心东医院作为特定机能病院,提供以重症疾病为中心的高级医疗服务,原则来说收治国际患者要经过正规的转诊程序,主要接收国外医院或诊所介绍来的患者。该院采取完全预约制,不接受当天的预约就诊。
百岁时代国际医疗是中信产业基金控股的新里程医院集团建设的国际医疗平台,作为国内少有的“医院派跨境医疗”,致力于为国内患者提供专业的海外医疗支持,与日本国立癌症研究中心东医院建立了国际转诊合作,通过医院之间的无缝转诊保证患者的就医质量。
- 上一篇:日本筑波大学附属病院质子治疗中心
- 下一篇:相泽医院 质子治疗中心